Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride

CE Cook, AR Jeffcoat, JM Hill, DE Pugh, PK Patetta, BM Sadler, WR White and M Perez- Reyes

Research Triangle Institute, Research Triangle Park, NC 27709-2194.

S-(+)-methamphetamine hydrochloride ("ice") is abused by smoking (inhaling the vapors of the material). Male human volunteers inhaled the drug from a pipe heated at 300 degrees-305 degrees C for an average inhaled dose of 21.8 +/- 0.3 (SE) mg. The same volunteers were given an intravenous injection of 15.5 mg of S-(+)-methamphetamine hydrochloride. Methamphetamine and its metabolite amphetamine were analyzed in plasma, saliva, and urine by gas chromatography. The bioavailability of smoked methamphetamine was 90.3 +/- 10.4%. (Oral bioavailability calculated from this study and a previous one was 67.2 +/- 3.1%). The geometric mean plasma half-life was 11.1 hr for smoked methamphetamine and 12.2 hr for the intravenous drug. These values agreed with urinary excretion rate data. The volume of distribution in the elimination phase was 3.24 +/- 0.36 liter/kg for the smoked dose and 3.73 +/- 0.59 liter/kg for the intravenous dose. The mean residence times were 11.5 +/- 0.5 hr and 11.3 +/- 1.74 hr for the two routes. Metabolic clearance represented 58 and 55%, respectively, of the total clearance. Significant amounts of the drug (37-45% of the nominal dose) were excreted in urine as methamphetamine and lesser amounts (7% of the nominal molar dose) as amphetamine. Renal clearance was equivalent for the two routes. Methamphetamine concentrations in plasma after inhalation showed a plateau. A model involving both a fast and a slow input function fit the data from 4 of the 6 subjects and indicated a terminal elimination rate that agreed with results from model- independent pharmacokinetic calculations. The drug caused significant subjective and cardiovascular effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 21, Issue 4, pp. 717-723, 07/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				A. D. Kalechstein, T. Fong, R. J. Rosenthal, A. Davis, H. Vanyo, and T. F. Newton Pathological Gamblers Demonstrate Frontal Lobe Impairment Consistent With That of Methamphetamine-Dependent Individuals J Neuropsychiatry Clin Neurosci, August 1, 2007; 19(3): 298 - 303. [Abstract] [Full Text] [PDF]

				J. Yuan, G. Hatzidimitriou, P. Suthar, M. Mueller, U. McCann, and G. Ricaurte Relationship between Temperature, Dopaminergic Neurotoxicity, and Plasma Drug Concentrations in Methamphetamine-Treated Squirrel Monkeys J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1210 - 1218. [Abstract] [Full Text] [PDF]

				R. J.F. Schepers, J. M. Oyler, R. E. Joseph Jr, E. J. Cone, E. T. Moolchan, and M. A. Huestis Methamphetamine and Amphetamine Pharmacokinetics in Oral Fluid and Plasma after Controlled Oral Methamphetamine Administration to Human Volunteers Clin. Chem., January 1, 2003; 49(1): 121 - 132. [Abstract] [Full Text] [PDF]

				J. M. Oyler, E. J. Cone, R. E. Joseph Jr, E. T. Moolchan, and M. A. Huestis Duration of Detectable Methamphetamine and Amphetamine Excretion in Urine after Controlled Oral Administration of Methamphetamine to Humans Clin. Chem., October 1, 2002; 48(10): 1703 - 1714. [Abstract] [Full Text] [PDF]

				M. Navarro, S. Pichini, M. Farre, J. Ortuno, P. N. Roset, J. Segura, and R. de la Torre Usefulness of Saliva for Measurement of 3,4-Methylenedioxymethamphetamine and Its Metabolites: Correlation with Plasma Drug Concentrations and Effect of Salivary pH Clin. Chem., October 1, 2001; 47(10): 1788 - 1795. [Abstract] [Full Text] [PDF]

				Y. Sekine, M. Iyo, Y. Ouchi, T. Matsunaga, H. Tsukada, H. Okada, E. Yoshikawa, M. Futatsubashi, N. Takei, and N. Mori Methamphetamine-Related Psychiatric Symptoms and Reduced Brain Dopamine Transporters Studied With PET Am J Psychiatry, August 1, 2001; 158(8): 1206 - 1214. [Abstract] [Full Text] [PDF]

				T. Ernst, L. Chang, M. Leonido-Yee, and O. Speck Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study Neurology, March 28, 2000; 54(6): 1344 - 1349. [Abstract] [Full Text] [PDF]

				G. J. Rivière, W. B. Gentry, and S. M. Owens Disposition of Methamphetamine and Its Metabolite Amphetamine in Brain and Other Tissues in Rats after Intravenous Administration J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1042 - 1047. [Abstract] [Full Text]

				G. J. Rivière, K. A. Byrnes, W. B. Gentry, and S. M. Owens Spontaneous Locomotor Activity and Pharmacokinetics of Intravenous Methamphetamine and Its Metabolite Amphetamine in the Rat J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1220 - 1226. [Abstract] [Full Text]